Idelalisib
- Generic Name
- Idelalisib
- Brand Names
- Zydelig
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18FN7O
- CAS Number
- 870281-82-6
- Unique Ingredient Identifier
- YG57I8T5M0
- Background
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...
- Indication
用于治疗：复发慢性淋巴细胞性白血病(CLL)，与利妥昔单抗联用，在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。
- Associated Conditions
- Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
- Conditions
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 202
- Registration Number
- NCT01090414
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT01088048
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.